Notice of Results

RNS Number : 6423P

Venture Life Group PLC

04 September 2017

 

Venture Life Group plc

("Venture Life" or the "Company")

Notice of Results

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, will announce its half year results for the six months ended 30 June 2017 on 21 September 2017.

A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Thursday 21 September 2017.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [e-mail].

 For further information please contact:

Venture Life Group PLC			[phone]
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser and Joint Broker)			[phone]
Matthew Johnson / Edward Hutton (Corporate Finance)
Bob Pountney / John Howes (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker)			[phone]
James Pope / Ben Turner
Walbrook PR	[e-mail] or + 44 (0) 20 7933 8780
Anna Dunphy / Paul McManus		[phone] / [phone]

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 

END

 

 

NOREFLFBDKFFBBL